Transforming growth factor-β1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis

Scott E. Evans, Thomas V. Colby, Jay H Ryu, Andrew Harold Limper

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Study objectives: Lymphangioleiomyomatosis (LAM) is a rare disorder of unknown etiology, affecting almost exclusively women of childbearing age, that is associated with the proliferation of spindle cells and cystic changes in the affected lung. The underlying processes that contribute to this disease are poorly understood. Transforming growth factor (TGF)-β1 is a potent cytokine that promotes mesenchymal cell proliferation and regulates the synthesis of extracellular matrix (ECM) components, particularly fibronectins. Herein, we evaluate the expression of TGFβ1 and matrix-associated fibronectin in lung specimens demonstrating LAM. Design: Lung biopsy specimens that were confirmed to contain pathologic LAM cells were obtained from 13 patients. The specimens were submitted to immunohistochemical evaluation for TGFβ1 and fibronectin, as well as the typical markers of LAM cells. Healthy lung parenchyma surrounding resected neoplasms was studied in a parallel fashion as control tissues. Measurements and results: In all 13 LAM cases and in healthy lung parenchyma, we demonstrated that TGFβ1 localized consistently to airway epithelial cells. However, in LAM tissues, matrix-associated TGFβ1 was also consistently found in regions containing pathologic LAM cells. Notably, more abundant TGFβ1 was observed in highly cellular areas compared to the walls of chronic cystic regions in LAM tissues. Fibronectin, a matrix component that is strongly expressed in response to active TGFβ 1 was found to consistently colocalize with this protein in these highly cellular regions, supporting TGFβ1 activity in these regions. The markers of proliferating LAM cells, including proliferating cell nuclear antigen, were also markedly present in these highly cellular LAM regions. Conclusion: These studies suggest that the proliferation of aberrant LAM cells may be associated with altered regional expression of TGFβ1 and related ECM proteins.

Original languageEnglish (US)
Pages (from-to)1063-1070
Number of pages8
JournalChest
Volume125
Issue number3
DOIs
StatePublished - Mar 2004

Fingerprint

Lymphangioleiomyomatosis
Transforming Growth Factors
Fibronectins
Extracellular Matrix
Lung
Cell Proliferation
Extracellular Matrix Proteins
Proliferating Cell Nuclear Antigen

Keywords

  • Fibronectins
  • Lymphangioleiomyomatosis
  • Transforming growth factor-β

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Transforming growth factor-β1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis. / Evans, Scott E.; Colby, Thomas V.; Ryu, Jay H; Limper, Andrew Harold.

In: Chest, Vol. 125, No. 3, 03.2004, p. 1063-1070.

Research output: Contribution to journalArticle

@article{606874c2596d46d69222c7fc0871c61c,
title = "Transforming growth factor-β1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis",
abstract = "Study objectives: Lymphangioleiomyomatosis (LAM) is a rare disorder of unknown etiology, affecting almost exclusively women of childbearing age, that is associated with the proliferation of spindle cells and cystic changes in the affected lung. The underlying processes that contribute to this disease are poorly understood. Transforming growth factor (TGF)-β1 is a potent cytokine that promotes mesenchymal cell proliferation and regulates the synthesis of extracellular matrix (ECM) components, particularly fibronectins. Herein, we evaluate the expression of TGFβ1 and matrix-associated fibronectin in lung specimens demonstrating LAM. Design: Lung biopsy specimens that were confirmed to contain pathologic LAM cells were obtained from 13 patients. The specimens were submitted to immunohistochemical evaluation for TGFβ1 and fibronectin, as well as the typical markers of LAM cells. Healthy lung parenchyma surrounding resected neoplasms was studied in a parallel fashion as control tissues. Measurements and results: In all 13 LAM cases and in healthy lung parenchyma, we demonstrated that TGFβ1 localized consistently to airway epithelial cells. However, in LAM tissues, matrix-associated TGFβ1 was also consistently found in regions containing pathologic LAM cells. Notably, more abundant TGFβ1 was observed in highly cellular areas compared to the walls of chronic cystic regions in LAM tissues. Fibronectin, a matrix component that is strongly expressed in response to active TGFβ 1 was found to consistently colocalize with this protein in these highly cellular regions, supporting TGFβ1 activity in these regions. The markers of proliferating LAM cells, including proliferating cell nuclear antigen, were also markedly present in these highly cellular LAM regions. Conclusion: These studies suggest that the proliferation of aberrant LAM cells may be associated with altered regional expression of TGFβ1 and related ECM proteins.",
keywords = "Fibronectins, Lymphangioleiomyomatosis, Transforming growth factor-β",
author = "Evans, {Scott E.} and Colby, {Thomas V.} and Ryu, {Jay H} and Limper, {Andrew Harold}",
year = "2004",
month = "3",
doi = "10.1378/chest.125.3.1063",
language = "English (US)",
volume = "125",
pages = "1063--1070",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - Transforming growth factor-β1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis

AU - Evans, Scott E.

AU - Colby, Thomas V.

AU - Ryu, Jay H

AU - Limper, Andrew Harold

PY - 2004/3

Y1 - 2004/3

N2 - Study objectives: Lymphangioleiomyomatosis (LAM) is a rare disorder of unknown etiology, affecting almost exclusively women of childbearing age, that is associated with the proliferation of spindle cells and cystic changes in the affected lung. The underlying processes that contribute to this disease are poorly understood. Transforming growth factor (TGF)-β1 is a potent cytokine that promotes mesenchymal cell proliferation and regulates the synthesis of extracellular matrix (ECM) components, particularly fibronectins. Herein, we evaluate the expression of TGFβ1 and matrix-associated fibronectin in lung specimens demonstrating LAM. Design: Lung biopsy specimens that were confirmed to contain pathologic LAM cells were obtained from 13 patients. The specimens were submitted to immunohistochemical evaluation for TGFβ1 and fibronectin, as well as the typical markers of LAM cells. Healthy lung parenchyma surrounding resected neoplasms was studied in a parallel fashion as control tissues. Measurements and results: In all 13 LAM cases and in healthy lung parenchyma, we demonstrated that TGFβ1 localized consistently to airway epithelial cells. However, in LAM tissues, matrix-associated TGFβ1 was also consistently found in regions containing pathologic LAM cells. Notably, more abundant TGFβ1 was observed in highly cellular areas compared to the walls of chronic cystic regions in LAM tissues. Fibronectin, a matrix component that is strongly expressed in response to active TGFβ 1 was found to consistently colocalize with this protein in these highly cellular regions, supporting TGFβ1 activity in these regions. The markers of proliferating LAM cells, including proliferating cell nuclear antigen, were also markedly present in these highly cellular LAM regions. Conclusion: These studies suggest that the proliferation of aberrant LAM cells may be associated with altered regional expression of TGFβ1 and related ECM proteins.

AB - Study objectives: Lymphangioleiomyomatosis (LAM) is a rare disorder of unknown etiology, affecting almost exclusively women of childbearing age, that is associated with the proliferation of spindle cells and cystic changes in the affected lung. The underlying processes that contribute to this disease are poorly understood. Transforming growth factor (TGF)-β1 is a potent cytokine that promotes mesenchymal cell proliferation and regulates the synthesis of extracellular matrix (ECM) components, particularly fibronectins. Herein, we evaluate the expression of TGFβ1 and matrix-associated fibronectin in lung specimens demonstrating LAM. Design: Lung biopsy specimens that were confirmed to contain pathologic LAM cells were obtained from 13 patients. The specimens were submitted to immunohistochemical evaluation for TGFβ1 and fibronectin, as well as the typical markers of LAM cells. Healthy lung parenchyma surrounding resected neoplasms was studied in a parallel fashion as control tissues. Measurements and results: In all 13 LAM cases and in healthy lung parenchyma, we demonstrated that TGFβ1 localized consistently to airway epithelial cells. However, in LAM tissues, matrix-associated TGFβ1 was also consistently found in regions containing pathologic LAM cells. Notably, more abundant TGFβ1 was observed in highly cellular areas compared to the walls of chronic cystic regions in LAM tissues. Fibronectin, a matrix component that is strongly expressed in response to active TGFβ 1 was found to consistently colocalize with this protein in these highly cellular regions, supporting TGFβ1 activity in these regions. The markers of proliferating LAM cells, including proliferating cell nuclear antigen, were also markedly present in these highly cellular LAM regions. Conclusion: These studies suggest that the proliferation of aberrant LAM cells may be associated with altered regional expression of TGFβ1 and related ECM proteins.

KW - Fibronectins

KW - Lymphangioleiomyomatosis

KW - Transforming growth factor-β

UR - http://www.scopus.com/inward/record.url?scp=1642406159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642406159&partnerID=8YFLogxK

U2 - 10.1378/chest.125.3.1063

DO - 10.1378/chest.125.3.1063

M3 - Article

C2 - 15006970

AN - SCOPUS:1642406159

VL - 125

SP - 1063

EP - 1070

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -